Williams, Harriet M.

Comprehensive evaluation of the 5xFAD mouse model for preclinical testing applications: A MODEL-AD study.

Oblak, A. L., Lin, P. B., Kotredes, K. P., Pandey, R. S., Garceau, D., Williams, H. M., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 325

Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H

Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 66

A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease

the MODEL-AD Consortium, Preuss, C., Pandey, R., Piazza, E., Fine, A., Uyar, A., Perumal, T., Garceau, D., Kotredes, K. P., Williams, H., et al. (2020) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 63

PIP2 depletion and altered endocytosis caused by expression of Alzheimer's disease‐protective variant PLCγ2 R522

Maguire, E., Menzies, G. E., Phillips, T., Sasner, M., Williams, H. M., Czubala, M. A., Evans, N., Cope, E. L., Sims, R., Howell, G. R., et al. (2021) · The EMBO Journal

Alzheimer's disease research and treatmentsCellular transport and secretion

Cited by 41

Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study

Onos, K. D., Quinney, S. K., Jones, D. R., Masters, A. R., Pandey, R., Keezer, K. J., Biesdorf, C., Metzger, I. F., Meyers, J. A., Peters, J., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 16

The Alzheimer’s disease protective P522R variant of PLCG2 , consistently enhances stimulus-dependent PLCγ2 activation, depleting substrate and altering cell function

Maguire, E., Menzies, G. E., Phillips, T., Sasner, M., Williams, H. M., Czubala, M. A., Evans, N., Cope, E. L., Sims, R., Howell, G. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory)

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 4